Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Multiple sclerosis (MS) causes neurological symptoms ... There’s no cure for MS, and the damage it causes cannot be reversed. Treatment typically involves disease-modifying therapies (DMTs ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Columnist Desiree Lama describes her journey with MS-related bladder problems that were brought under control but are now ...

The drug is designed to reduce inflammation in the brain and has been used on MS, cancer and migraine headaches.

FH is a genetic condition of very high cholesterol levels that presents a high risk for coronary artery disease.

Royalty Pharma is giving Biogen $250 million for its lupus treatment litifilimab, which is currently in Phase 3 development ...

According to Grand View Research, the global multiple sclerosis treatment market has been experiencing steady growth, driven by advancements in therapeutic options and a rising prevalence of the ...

Cosmos Health (COSM) announced the filing of a patent application for treatment for multiple sclerosis, a disabling autoimmune disorder affecting millions worldwide. The patent is supported by ...

The Floodlight MS app, used to track disease progression in people with multiple sclerosis, has been deemed cost-effective in ...